Brokerages Anticipate Exact Sciences Co. (NASDAQ: EXAS) to Report Quarterly Sales of $ 430.29 Million



Stock analysts predict that Exact Sciences Co. (NASDAQ: EXAS) will report revenue of $ 430.29 million for the current quarter, Zacks investment research reports. Seven analysts have estimated the profits of Exact Sciences. The highest sales estimate is $ 440.10 million and the lowest is $ 421.20 million. Exact Sciences reported $ 408.36 million in revenue in the same quarter last year, which would indicate a positive growth rate of 5.4% year-over-year. The company is expected to announce its next quarterly earnings report on Tuesday, October 26.

According to Zacks, analysts expect Exact Sciences to report annual revenue of $ 1.73 billion for the current fiscal year, with estimates ranging from $ 1.72 billion to 1.74 billion billion dollars. For the next fiscal year, analysts predict the company will post revenue of $ 2.10 billion, with estimates ranging from $ 1.93 billion to $ 2.22 billion. Zacks sales averages are an average based on a survey of analysts who cover Exact Sciences.

Exact Sciences (NASDAQ: EXAS) last released its results on Tuesday, July 27. The medical research company reported ($ 1.03) earnings per share for the quarter, missing analyst consensus estimates of ($ 0.72) by ($ 0.31). Exact Sciences has a negative net margin of 50.52% and a negative return on equity of 8.93%. The company posted revenue of $ 434.82 million in the quarter, compared to analysts’ estimates of $ 418.76 million.

A number of equity analysts recently commented on the stock. Canaccord Genuity lowered its price target for Exact Sciences stock from $ 185.00 to $ 160.00 and set a “buy” rating on the stock in a report released on Thursday, July 29. Stifel Nicolaus lowered his target price on Exact Sciences shares from $ 165.00 to $ 145.00 and set a “buy” rating on the stock in a report released Thursday, July 29. Wells Fargo & Company raised its price target for Exact Sciences stock from $ 115.00 to $ 120.00 and gave the stock an “equal weight” rating in a report released on Monday, June 21. Zacks investment research downgraded Exact Sciences shares from a “custody” rating to a “strong sell” rating and set a target price of $ 88.00 for the company. in a research note on Wednesday, September 29. Finally, Raymond James launched coverage on Exact Sciences shares in a research note on Tuesday, June 15. They set a “strong buy” rating and a target price of $ 160.00 for the company. One stock research analyst rated the stock with a sell rating, four issued a conservation rating, twelve assigned a buy rating, and one assigned a high buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $ 146.94.

(A d)

A popular Seattle cannabis maker is now teaming up with other companies to produce a new line of cannabis-infused drinks. It’s the perfect timing. A new report reveals that sales of cannabis drinks will reach $ 2.8 billion by 2025, growing at a compound annual rate of 17.8%. A huge opportunity!

Actions of Exact science actions open for $ 93.20 Tuesday. Exact Sciences has a fifty-two week minimum of $ 89.65 and a fifty-two week maximum of $ 159.54. The company has a debt to equity ratio of 0.53, a current ratio of 2.47, and a quick ratio of 2.34. The company has a market cap of $ 16.03 billion, a P / E ratio of -17.07 and a beta of 1.29. The company’s 50-day moving average price is $ 101.72, and its two-hundred-day moving average price is $ 113.61.

In related news, CFO Jeffrey Thomas Elliott sold 38,361 shares of the company in a transaction that took place on Thursday, July 29. The shares were sold at an average price of $ 111.40, for a total trade of $ 4,273,415.40. The sale was disclosed in a legal file with the SEC, which can be accessed through this hyperlink. In addition, principal Katherine S. Zanotti sold 1,381 shares of the company in a transaction that took place on Friday, July 30. The shares were sold at an average price of $ 111.11, for a total trade of $ 153,442.91. As a result of the sale, the Director now owns 34,741 shares of the company, valued at $ 3,860,072.51. Disclosure of this sale can be found here. 1.40% of the shares are currently owned by insiders.

Several hedge funds have recently changed their positions in EXAS. Achmea Investment Management BV acquired a new stake in Exact Sciences during the 1st quarter for a value of approximately $ 624,000. The New York State Common Retirement Fund increased its stake in Exact Sciences by 14.2% during the 1st quarter. The New York State Pooled Retirement Fund now owns 618,330 shares of the medical research company valued at $ 81,484,000 after acquiring an additional 76,818 shares during the period. Rockefeller Capital Management LP increased its stake in Exact Sciences by 64.4% during the 1st quarter. Rockefeller Capital Management LP now owns 16,625 shares of the medical research company valued at $ 2,190,000 after acquiring an additional 6,513 shares during the period. First Horizon Advisors Inc. increased its stake in Exact Sciences by 172.3% during the 1st quarter. First Horizon Advisors Inc. now owns 1,089 shares of the medical research company valued at $ 143,000 after acquiring an additional 689 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in Exact Sciences by 23.3% during the first quarter. Teacher Retirement System of Texas now owns 17,517 shares of the medical research company valued at $ 2,308,000 after acquiring an additional 3,311 shares during the period. Institutional investors hold 88.31% of the shares of the company.

Company Profile Exact Sciences

EXACT Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. She developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Recommended Story: Most volatile stocks

Get a free copy of Zacks’ Exact Sciences Research Report (EXAS)

For more information on Zacks Investment Research’s research offerings, visit

History and earnings estimates for the exact sciences (NASDAQ: EXAS)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in the exact sciences now?

Before you consider the exact sciences, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and Exact Sciences was not on the list.

Although Exact Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Leave A Reply

Your email address will not be published.